Key result
ARBs provide an effective alternative to ACE inhibitors, particularly in ACE-intolerant patients.
Why the study?
The limitations of ACE inhibitors and the therapeutic role of ARBs in hypertension, heart failure, and diabetic nephropathy require clarification.
Do ARBs provide similar clinical efficacy and better tolerability compared to ACE inhibitors in patients with hypertension, heart failure, or diabetic nephropathy?
Population
Patients with hypertension, heart failure, or diabetic nephropathy
Comparison
Angiotensin II-receptor blockers vs angiotensin-converting-enzyme inhibitors
Design
Review
Authors
Loading...
Supports ARB use in ACEI-intolerant patients; leaves open need for updated head-to-head trials in tolerant populations.
Do ARBs provide similar clinical efficacy and better tolerability compared to ACE inhibitors in patients with hypertension, heart failure, or diabetic nephropathy?
ARBs are an effective and better-tolerated alternative to ACE inhibitors for patients with hypertension, heart failure, or diabetic nephropathy who cannot tolerate ACE inhibitors.
Rodgers et al. (2001) conducted a review in Hypertension, heart failure, and diabetic nephropathy. Angiotensin II-receptor blockers (ARBs) vs. Angiotensin-converting-enzyme (ACE) inhibitors was evaluated. Angiotensin II-receptor blockers provide an effective alternative to ACE inhibitors for managing hypertension, heart failure, and diabetic nephropathy, particularly in ACE-inhibitor-intolerant patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: